Health & Fitness
9 min read
Revolutionary Tech for Early Chronic Kidney Disease Diagnosis
Bioscience Association Manitoba
January 19, 2026•3 days ago

AI-Generated SummaryAuto-generated
A startup, AssureCKD, is developing rapid, affordable lab-on-a-chip technology called MATLOC for early chronic kidney disease diagnosis. This innovation, backed by federal funding, aims to provide point-of-care testing, making early detection more accessible globally. The technology is preparing for regulatory clearance, with hopes of reducing healthcare costs and improving patient outcomes.
Chronic kidney disease (CKD) affects close to a billion people globally, often leading to organ failure due in part to the current high cost and complexity of lab tests.
The UM-affiliated startup AssureCKD is creating rapid and affordable lab-on-a-chip technology called MATLOC, that could be administered anywhere in the world at a patient’s point-of-care. This technology represents more than a decade of research by a UM inventor team led by Dr. Claudio Rigatto and Dr. Francis Lin.
“Kidney disease has become a huge problem with, nearly one in ten Canadians affected it’s clear that new tools for early diagnosis are in urgent need,” says Francis Lin, Professor, UM Department of Physics and Astronomy (Faculty of Science) and Department of Immunology (Rady Faculty of Health Sciences).
New funding for accessible tools
Although effective tools for the diagnosis of kidney disease already exist, successful treatment depends on timely detection – before the obvious signs of disease become apparent. Routine tests are limited to specialized labs, making them inaccessible in many cases.
Earlier this year AssureCKD announced new major federal funding with Drs Rigatto and Lin to support continued development of easy-to-use test kits.
“As a kidney specialist, the most heartbreaking experience is seeing the emergency of kidney failure and knowing it could have been prevented through early detection,” says Claudio Rigatto, Professor, UM Department of Internal Medicine (Rady Faculty of Health Sciences).
“We’ve done screening in Northern communities that cost thousands and required the transport of hundreds of pounds of equipment. With MATLOC, we will soon be reducing the test to much lower cost that can be done at your doctor’s office during a routine visit.”
Innovation to Impact
MATLOC is now preparing for regulatory clearance in Canada and the United States and is expected to become a clinical and commercial reality in the near future.
“We’ve been lucky to have great support from UM on our day-to-day research operation, helping with recruitment and training of research personnel, and facilitating academic collaboration and industry partnership,” says Lin. “With universally accessible screening tools for early detection of kidney disease, there is hope that we can improve lives for patients and significantly reduce healthcare costs for everyone.” The push to preventative care is a central tenet for the growing eight-member AssureCKD(external link) & UM collaborating R&D team. New groundbreaking research from their Fort Garry Campus lab has led to a recent publication in the high impact journal Sensors and Actuators B: Chemical(external link) , outlining the progress of the MATLOC technology toward kidney disease prevention for future generations.
For more information on turning research into impact through partnership and collaboration, visit our website(external link) .
Rate this article
Login to rate this article
Comments
Please login to comment
No comments yet. Be the first to comment!
